Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.
WINNERS
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Code | Company | Price | % | Volume | Market Cap |
---|
JAV | Javelin Minerals Ltd | 0.0015 | 50% | 1,000,000 | $9,454,152.77 |
MEB | Medibio Limited | 0.002 | 33% | 1,250,000 | $4,980,890.69 |
NRX | Noronex Limited | 0.044 | 26% | 685,341 | $5,966,092.55 |
SGQ | St George Min Ltd | 0.032 | 23% | 5,216,139 | $18,200,463.01 |
ROG | Red Sky Energy. | 0.006 | 20% | 80,944,703 | $26,511,135.99 |
TMS | Tennant Minerals Ltd | 0.048 | 20% | 28,139,790 | $24,663,050.60 |
MCM | Mc Mining Ltd | 0.35 | 17% | 46,739 | $59,296,461.00 |
NAE | New Age Exploration | 0.007 | 17% | 821,864 | $8,615,393.46 |
CTO | Citigold Corp Ltd | 0.008 | 14% | 543,079 | $19,835,613.64 |
SI6 | SI6 Metals Limited | 0.008 | 14% | 98,803 | $10,417,323.55 |
Wordpress Table Plugin
Explorer St George Mining (ASX:SGQ) says there is also “significant lithium potential” at the Mt Alexander nickel-copper-PGE project in WA.
“We will advance the lithium exploration in tandem with drill testing several very promising, recently identified nickel targets announced on 1 September 2022,” SGQ boss John Prineas says.
And Tennant Minerals (ASX:TMS) has hit up to 54.5% copper and 39 g/t gold in latest drilling at the Bluebird discovery in the NT.
LOSERS
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Code | Company | Price | % | Volume | Market Cap |
---|
NSB | Neuroscientific | 0.105 | -51% | 1,336,753 | $30,846,403.25 |
ANL | Amani Gold Ltd | 0.001 | -33% | 2,499,999 | $35,540,161.69 |
LNU | Linius Tech Limited | 0.004 | -20% | 2,000,000 | $11,569,331.56 |
HAS | Hastings Tech Met | 4.4 | -19% | 603,087 | $549,851,547.50 |
AMT | Allegra Orthopaedics | 0.14 | -18% | 178 | $17,758,064.51 |
PRX | Prodigy Gold NL | 0.012 | -14% | 3,008,414 | $8,156,786.48 |
ADR | Adherium Ltd | 0.008 | -11% | 106,777 | $20,049,259.82 |
AUH | Austchina Holdings | 0.008 | -11% | 30,000 | $18,331,494.59 |
NZS | New Zealand Coastal | 0.004 | -11% | 6,634 | $5,071,522.64 |
PNX | PNX Metals Limited | 0.004 | -11% | 2,736,388 | $19,998,260.13 |
Wordpress Table Plugin
The Human Research Ethics Committee (HREC) has rejected NeuroScientific Biopharmaceuticals’ (ASX: NSB) planned Phase I Clinical Trial for EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma.
“Australia’s next rare earths producer” Hastings Technology Metals (ASX:HAS) will raise $110m at a discounted $4.40/share to accelerate development of the Yangibana REE project.
You might be interested in